

October 6, 2022

BrightPath to Update the Pre-clinical Data of iPS-NKT, BP1202 and BP1212 at SITC 2022

Tokyo, Japan - October 6, 2022/ -- BrightPath Biotherapeutics (TSE Growth 4954), a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutics, today announced that Company will present that pre-clinical data on iPS-NKT, BP1202(anti-CD39 antibody) and BP1212(anti-TIM3 and CD39 bispecific antibody) will be presented at the Society for Immunotherapy of Cancer Annual Meeting (SITC 2022, November 8-12, Boston). Summary of the abstract and the electronic poster will be posted on the website of BrightPath after SITC 2022 is held.

- A novel iPSC-derived CAR-invariant natural killer T (iNKT) cell therapy platform for hematologic malignancies and solid tumors (Abstract number: 290)
- BP1202-NF2, a novel ADCC-enhancing CD39 antibody, induces destruction of regulatory T cells and enhances cytotoxic T lymphocytes induction (Abstract number:1221)
- Bispecific antibodies that block TIM-3 and CD39 induce anti-tumor efficacy and immune response by blocking multiple suppressive mechanisms. (Abstract number:1364)

Date & Time: 9 a.m.-9 p.m. EST on Thursday, November 10, 2022

About BrightPath:

BrightPath is a clinical stage biopharmaceutical company focused on the development of novel cancer immuno-therapies to transform cancer treatment for refractory or progressive cancers that cannot be treated with conventional standard therapies. BrightPath is actively involved in developing cell therapies currently in clinical trials, immunomodulatory antibodies and new drug targeted at cancer specific neoantigens.

For more information, visit www.brightpathbio.com

Investor and Media Contact:

+81-3-5840-7697

irpr@brightpathbio.com

www.brightpathbio.com